Amgen To Present New Data From Repatha ® (evolocumab) Clinical Trials At ACC.18

Presentations Focus on Patients With Established Cardiovascular Disease and Include Data Exploring Consistency of LDL-C Reduction With Repatha New Data Shows Patients at High Risk for Cardiovascular Events Continue to be Denied PCSK9 Inhibitors THOUSAND OAKS, Calif., Feb. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the Repatha® (evolocumab) clinical trial program to be featured at the American College of Cardiology's 67th Annual Scientific Session (ACC.18) in Orlando, Fla., March 10-12, 2018. Presentations to include additional analyses from the Repatha cardiovascular outcomes trial (FOURIER) and the Repatha coronary intravascular ultrasound i...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news